|
|
Article: Concurrent Pharma Takes Over Allergan's Retinoids For Equity.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Acquiring the same development team that discovered the topical tazarotene known as Tazorac - though not rights to the acne drug itself - Concurrent Pharmaceuticals Inc. has bought a portfolio of near-clinical compounds from Allergan Inc.'s retinoid and rexinoid nuclear receptor drug program.
"I would call it a logical extension of our core activities," said Jeffrey Hatfield, recently appointed CEO of the Fort Washington, Pa.-based firm, which he described as a small-molecule biotechnology company focused on kinases, nuclear receptors and enzyme inhibitors.
Privately held Concurrent, which has a lead drug discovery program in ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|